Sahil Praikh explains key endovascular takeaways at TCT 2025

Endovascular therapies took center stage at TCT 2025 in San Francisco, signaling a shift in interventional cardiology toward treating more vascular diseases beyond the heart.

"We're excited to see endovascular medicine having a renaissance at TCT," Sahil Parikh, MD, TCT program director, said in an interview with Cardiovascular Business. Parikh, director of endovascular services at Columbia University Irving Medical Center and associate professor of medicine at Columbia University, said pulmonary embolism (PE), stroke, peripheral artery disease (PAD) and renal denervation are now at the forefront of innovation and gaining interest at conferences.

Two late-breaking clinical trials presented on the opening day highlighted the field’s rapid momentum. The STORM-PE trial was a landmark randomized study comparing mechanical thrombectomy using the Penumbra Indigo Lightning Flash system against standard anticoagulation therapy for acute PE in intermediate-risk patients. The results showed a significant reduction in the right ventricular-to-left ventricular ratio, an important marker of right heart strain relief. He said STORM-PE was a groundbreaking trial in PE, probably the first of several, that may start to unlock the guidelines with new and more effective interventional therapies.